nach oben

Clinical and Translational Oncology

Erschienen in:

13.06.2017 | Review article

Supportive care in pancreatic ductal adenocarcinoma

verfasst von: B. Laquente, A. Calsina-Berna, A. Carmona-Bayonas, P. Jiménez-Fonseca, I. Peiró, A. Carrato

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy. Symptomatic management should be accomplished in a multidisciplinary fashion. Its primary aims include relief of biliary or duodenal obstruction, prevention and/or treatment of thromboembolic disease, and control cancer-related pain. Nutritional support and optimal replacement therapy in patients with endocrine and/or exocrine insufficiency, is mandatory. This manuscript highlights the most significant problems faced when caring for patients with advanced PDAC and provides an evidence-based approach to symptomatic management.

http://globocan.iarc.fr. GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, Accessed February 2016.

Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.CrossRefPubMed

Stark A, Hines OJ. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:163–76.CrossRefPubMed

Huguier M, Baumel H. Surgical palliation for unresected cancer of the exocrine pancreas. Eur J Surg Oncol. 1993;19:342–7.PubMed

Glazer ES, Hornbrook MC. A metaanalysis of randomized trials: immediate stent replacement vs surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manag. 2014;47:307–14.CrossRef

Pinol V, Castells A. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprotheses for treating malignant biliary obstruction: randomized clinical trial. Radiology. 2002;225:27–34.CrossRefPubMed

Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007;33:213–21.CrossRefPubMed

Kitano M, Yamashita Y, Tanaka K, Konishe H, Yazui S, Nakai Y, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013;108:1713–22.CrossRefPubMed

de Rooij PD, Rogatko A, Brennan MF. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg. 1991;78:1053–8.CrossRefPubMed

10.

Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centres. Ann Surg. 2005;242:540–7.PubMedPubMedCentral

11.

vanHooft JE, van Montfoort ML, Jeurnink SM, Bruno MJ, Dijkgraaf MG, Siersema PD, Fockens P. Safety and efficacy of a new non-foreshortening nitinol stent in malignant gastric outlet obstruction (DUONITI study): a prospective, multicenter study. Endoscopy. 2011;43:671–5.CrossRef

12.

van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD, Dijkgraaf MGW, Fockens P. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69:1059–66.CrossRefPubMed

13.

Hosono S, Ohtani H, Arimoto Y, Kanamiya Y. Endoscopic stenting versus surgical gastroenterostomy for palliation of malignant gastroduodenal obstruction: a meta-analysis. J Gastroenterol. 2007;42:283–90.CrossRefPubMed

14.

Davis M. Integrating palliative care into oncology practice. Am J Hosp Palliat Care. 2005;22:447–56.CrossRefPubMed

15.

Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block (CPB) is thought to be a safe and effective technique for reducing the severity of pain. Cochrane Database Syst Rev. 2011;3:CD007519.

16.

Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2007;102:430–43.CrossRefPubMed

17.

http://www.who.int/cancer/palliative/painladder/en. Accessed Feb 2016.

18.

http://www.nccn.org/professionals/physician_gls/PDF/pain.pgf, National Comprehensive Cancer Network, Adult Cancer Pain Guidelines. http://www.nccn.org/professionals/physician_gls/PDF/pain.pgf. Accessed Feb 2016.

19.

Foley K. Pain syndromes and pharmacological management of pancreatic cancer pain. J Pain Symptom Manag. 1988;3:176–87.CrossRef

20.

Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, et al. Morphine versus oxycodone in pancreatic cancer pain. A randomized controlled study. Clin J Pain. 2010;26:794–7.CrossRefPubMed

21.

Erdek MA, King LM, Ellsworth SG. Pain management and palliative care in pancreatic cancer. Curr Probl Cancer. 2013;37:266–72.CrossRefPubMed

22.

Stearns L, Boortz-Marx R, Du Pen S, Friechs G, Gordon M, Halyard M, et al. Intratecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3:399–408.PubMed

23.

Niu L, Wang Y, Yao F, Wei C, Chen Y, Zhang L, et al. Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. Cryobiology. 2013;66:105–11.CrossRefPubMed

24.

Chen H, Liu TY, Kuai L, Zhu J, Wu CJ, Liu LM. Electroacupuncture treatment for pancreatic cancer pain: a randomized controlled trial. Pancreatology. 2013;13:594–7.CrossRefPubMed

25.

Bahn BM, Erdek MA. Celiac plexus block and neurolysis for pancreatic cancer. Curr Pain Headache Rep. 2013;17:310–3.CrossRefPubMed

26.

Wyse JM, Carone M, Paquin SC. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011;26:3541–6.CrossRef

27.

Mercadante S, Klepstad P, Kurita GP, Sjogren P, Giarratano A, Euopean Palliative Care Research Collaborative (EPCRC). Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96:577–83.CrossRefPubMed

28.

Smith T, Temin S, Alesi E. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30:880–7.CrossRefPubMed

29.

Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manag. 1988;3:199–205.CrossRef

30.

Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, Moran GR, Mourtzakis M. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr. 2013;109:302–12.CrossRefPubMed

31.

Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr. 2006;25:245–59.CrossRefPubMed

32.

August DA, Huhmann MB. ASPEN clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN. 2009;33:472–500.CrossRef

33.

Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–72.CrossRefPubMed

34.

Bauer J, Capra S, Fergunson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56:779–85.CrossRefPubMed

35.

Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.CrossRefPubMed

36.

Bozzetti F. Perioperative nutritional support in the ERAS approach. Clin Nutr. 2013;32:872–3.CrossRefPubMed

37.

Bartel MJ, Asbun H, Stauffer J, Raimondo M. Pancreatic exocrine insufficiency in pancreatic cancer: a review of the literature. Dig Liver Dis. 2015;47:1013–20.CrossRefPubMed

38.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRefPubMed

39.

Joglekar S, Asghar A, Mott SL. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;111:771–5.CrossRefPubMed

40.

Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:2416–23.CrossRefPubMed

41.

Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KCH, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.CrossRefPubMed

42.

Zalite IO, Zykus R, González MF, Saygili F, Pukitis A, Gaujoux S, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology. 2015;15:19–24.CrossRef

43.

Ruiz García V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310.

44.

Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106:371–8.CrossRefPubMed

45.

Shaib W, Deng Y, Zilterman D, Lundberg B, Saif MW. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res. 2010;30:4261–4.PubMed

46.

Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, et al. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model. Clin Trans Oncol. 2014;10:927–30.CrossRef

47.

Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer. 2012;118:3053–61.CrossRefPubMed

48.

Ögren M, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH. Trousseau’s syndrome—what is the evidence? A population-based autopsy study. Thromb Haemost. 2006;95:541–5.PubMed

49.

Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer. 1938;34:566–85.

50.

Wang JG, Geddings JE, Aleman MM, Cardena JC, Ghantratahmmachart P, Williams JC, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012;119:5543–52.CrossRefPubMedPubMedCentral

51.

Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013;132:180–4.CrossRefPubMed

52.

Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122:2011–8.CrossRefPubMed

53.

Tesselaar MET, Romijn FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–7.CrossRefPubMed

54.

Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–5.CrossRefPubMed

55.

Nakchbandi W, Müller H, Singer MV, Löhr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol. 2006;41:1095–104.CrossRefPubMed

56.

Van Doormaal FF, Di Nisio M, Otten H-M, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29:2071–6.CrossRefPubMed

57.

Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol. 2008;47:337–46.CrossRefPubMed

58.

Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028–34.CrossRefPubMed

59.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.CrossRefPubMedPubMedCentral

60.

Kuderer NM, Ortel TL, Khorana AA, Francis CW, Lyman GH. Low molecular weight heparin thromboprophylaxis in ambulatory cancer patients: a systematic review and meta-analysis of randomized controlled trials. Blood. 2009;114:203–6.

61.

Riess H, Pelzer U, Opitz B, Stauch M, Reitzig P, Hanhnfeld S, Müller HL, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. In: ASCO Annual Meeting Proceedings. 2010;28:15s.

62.

Maraveyas A, Waters J, Roy R, Fyfe D, Prooper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283–92.CrossRefPubMed

63.

Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega Garcia P, MartÍn Jimenez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014;16:1079–90.CrossRefPubMedPubMedCentral

64.

Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Cancer Netw. 2017;15:370–98.CrossRef

65.

Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22:vi85–92.CrossRefPubMed

66.

Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442–4.CrossRefPubMed

Titel: Supportive care in pancreatic ductal adenocarcinoma
verfasst von: B. Laquente
A. Calsina-Berna
A. Carmona-Bayonas
P. Jiménez-Fonseca
I. Peiró
A. Carrato
Publikationsdatum: 13.06.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 11/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1682-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Supportive care in pancreatic ductal adenocarcinoma

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases

A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients

Erratum to: Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer

A logistic regression model predicting high axillary tumour burden in early breast cancer patients

Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie